India's Sakar Healthcare up on eyeing anti-cancer business expansion abroad
** Shares of Sakar Healthcare SAKA.NS rise as much as
12.7%, last up 9.1% at 346.6 rupees
** Co starts product dossier submission overseas in its
anti-cancer segment
** Stock on track for best day since Dec. 26
** Nearly 129,000 shares traded so far, stock's busiest day
since March 6
** Stock down ~13% YTD vs 20.5% climb in Nifty Pharma index
.NIPHARM which SAKA is not a part of
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Sakar Healthcare
See all newsIndia's Sakar Healthcare jumps on regulatory approvals for cancer drugs
Brief: Sakar Healthcare Gets 14 Oncology Product New Approvals In EU, UK, Canada With 7 Business Partners
Brief: Sakar Healthcare Says Co Added To Manufacturing Of Accord's (UK) Finished Product Imatinib Accord
Australia's Algorae Pharmaceuticals rises on licensing deal with Sakar Healthcare
Brief: Algorae Pharmaceuticals Signs Exclusive License Agreement With Sakar